TORONTO and WINNIPEG, Aug. 16 /CNW/ - Cangene Corporation today reports
that its contract with the U.S. Centers for Disease Control and Prevention for
the supply of Vaccinia Immune Globulin Intravenous (Human) ("VIG") has been
extended for five more years. The original five-year contract was signed in
August 2002, and under that contract Cangene developed and delivered VIG
product to the U.S. Strategic National Stockpile ("SNS"). Although a supply of
product is already maintained within the SNS, the extended contract supports
licensing requirements, ongoing stability studies, further clinical testing
and development projects, and could provide for future orders.
